Back to announcement
20260513_OMED_Laporan Informasi dan Fakta Material_32091060_lamp2.pdf
Other Text extracted OMEDSource file signed link, expires in 15 minutes
Extracted text 5
Page 1
3M 2026 Result:
Strong Start to 2026 with Accelerated Growth and
Improving Profitability
INVESTOR BULLETIN COMPANY HIGHLIGHTS
• OMED delivered strong financial and operational performance
in 1Q2026, with broad-based growth across revenue, profitability,
May 12, 2025 and sales volume. Revenue reached IDR 572 billion, a robust increase
of 31.2% YoY from IDR 436 billion in 1Q2025. Gross profit grew to
Share Price Data (as of May 12, 2026): IDR 206 billion, with gross margin expanding to 36.0% from 33.7% in
1Q2025, driven by volume scale and improved factory overhead
Ticker on IDX OMED absorption. EBITDA reached approximately IDR 132 billion,
representing a margin of 23.0%. Net profit came in at IDR 99 billion,
Last Closing Price (IDR): 248 with a net margin of 17.3%, up from 16.8% in 1Q2025.
Outstanding Shares (Bn): 27.06 • Balance sheet remains solid, with total assets of IDR 3.32 trillion,
total liabilities of IDR 470 billion, and total equity of IDR 2.85 trillion.
Market Cap (IDR Tn): 6.55T Liquidity is strong, with a current ratio of 11.1x and an interest-
bearing debt-to-equity ratio of just 0.01x, underscoring OMED's
virtually debt-free position. The cash conversion cycle improved to 202
days in 1Q2026 from 217 days in 1Q2025, driven by faster receivable
Shareholder Structure (Mar 31, 2026): collection (46 days vs. 53 days) and stable payable terms.
PT Intisumber Hasilsempurna (%): 83.30
STRATEGIC OUTLOOK
Yacobus Jemmy Hartanto (%): 0.94
OMED is executing on four key growth initiatives heading into the second
Siane Soetanto (%): 0.90 half of 2026.
Treasury Shares (%): 0.19 • IOL Launch (Q4-2026). OMED is preparing to launch a locally
manufactured Intraocular Lens, targeting Indonesia's large and
Public (%): 14.67 underserved cataract market. With 80% of Indonesia's 1.6 million
blindness cases caused by cataracts and a Cataract Surgical Rate 2–3x
below regional peers, the domestic IOL opportunity remains
significantly underpenetrated.
Contact us:
• Philippines Export. OMED is extending its export reach into the
Corporate Secretary & Investor Relation
Philippines, complementing its broader China +1 positioning as a
Email: reliable Southeast Asian manufacturing base for regional and U.S.
buyers.
corporate.secretary@onemed.co.id
ir@onemed.co.id • New Retail Stores. OMED continues to expand its OneMed Medicom
retail network, deepening last-mile access to medical supplies across
Website: Indonesia.
www.onemed.co.id
• NDC Jakarta. A new National Distribution Center in Jakarta is coming
soon, set to strengthen logistics capacity and support OMED's growing
distribution scale across all customer segments.
Company’s Presence Across Country
Sumatera
2 National Distribution
Centers (1 Under
Kalimantan Sulawesi Renovation)
22 Branch offices and
Maluku warehouses
Papua
10 Sales offices
Bali Lombok
Java Flores 27 Omnichannel
27 Omnichannel
Stores
Stores
Page 2
Strong Volume-Led Growth, Supported by Government Healthcare Spending
Tailwinds
Revenue by Customer Profile Contribution
Growth
IDR Bn 3M25 3M26 3M25 3M26
(YoY)
Private 308 361 18% 70.5% 63.2%
Government 127 207 64% 29.0% 36.3%
Export 1.8 3.0 72% 0.4% 0.5%
Total 436 572 31% 100% 100%
Source: Company
Revenue growth in 1Q2026 was broad-based across all customer segments, reaching IDR 572 billion (+31.2%
YoY). Government segment was the standout, surging 64% YoY to IDR 207 billion, with its revenue contribution
expanding meaningfully from 29.0% to 36.3%, reflecting strengthening public healthcare spending and OMED's
deepening penetration of government procurement channels. The Private segment grew a solid 18% YoY to IDR
361 billion, though its contribution moderated from 70.5% to 63.2% as government spending accelerated at a
faster pace. Export revenues, while still small in absolute terms, grew 72% YoY to IDR 3 billion, with its
contribution ticking up from 0.4% to 0.5%, an early signal of OMED's nascent but growing international
presence.
Production Capacity & Utilization Update
Production Capacity Utilization Manufacturing capacity has
Product (Unit ‘000.000) Rate been expanded selectively over
Product
Category 2023–2025, with notable additions
2023 2024 2025 2025
in Wound Care (+27.4%), Syringes
Mask 550 599 599 60.1% & Needles (+13.4%), and Swab
Products (+25.2%), all segments
Underpad 60 75 75 34.6% experiencing strong volume
Disposable & demand.
Infusion Set and IV 50 50 50 58.0%
Consumable
Syringes and Needles 500 500 567 75.7% Utilization rates reflect a healthy
operational profile, with Wound
Foley Catheter 1,2 2,7 2,7 29.6%
Care (86.0%), Antiseptic Liquid
Antiseptic Liquid 24 24 24 84.2% (84.2%), and Syringes & Needles
(75.7%) running at high levels.
Swab Products 770 964 964 50.6%
Antiseptic &
Dialysis
Antiseptic Gel 5,0 5,0 5,0 48.0%
Meanwhile, meaningful spare
capacity in categories such as
Dialysis Fluid 2,7 2,7 2,7 33.3% Underpad, Dialysis Fluid, and Foley
Catheter provides OMED with
Pregnancy Test 75 75 75 41.3%
Biotechnology flexibility to absorb incremental
& Laboratory volume growth, without near-term
Blood Collection Tube 10 10 10 2.0%
capex pressure.
Diagnostic &
Patient Monitors 0,003 0,003 0,003 33.3%
Equipment
Wound Care Wound Care 270 327 344 86.0%
Source: Company
Page 3
New National Distribution Center, Jakarta
Figure 1: NDC Jakarta OMED is set to open its second National Distribution Center
(NDC) in Pulo Gadung, Jakarta, estimated to commence
operations in May 2026. With a warehouse size of
approximately 5,000 sqm, the Jakarta NDC will complement
OMED's existing NDC in Gresik, East Java (±30,000 sqm,
operational since 2007), which currently serves the eastern
part of Indonesia. The new Jakarta facility will extend OMED's
logistics coverage to the western part of Indonesia, enabling
faster and more efficient product delivery to customers across
the country's most densely populated and economically active
region. This infrastructure investment directly supports
OMED's growing distribution scale and reinforces its ability to
serve government, private, and export customers with
Source: Company greater speed and reliability.
New Product: IOL (Intraocular Lens)
Figure 2: Cataract Statistics OMED is preparing to launch a locally manufactured
Intraocular Lens (IOL) in Q4-2026, entering one of
Indonesia's most underpenetrated medical device segments.
IOL is the only definitive solution for cataracts, a condition
where the eye's natural lens becomes cloudy, obstructing
light from reaching the retina and causing a decline in visual
quality. The procedure involves removing the clouded lens
million
and replacing it with a clear artificial IOL implant, restoring
the patient's vision.
Globally, 94 million people live with cataracts and 50% have
not yet received the surgery they need, out of 2.2 billion
people experiencing near or distance vision impairment
worldwide. In Indonesia, the burden is particularly acute,
with approximately 1.6 million blindness cases have been
recorded, of which 80% are caused by cataracts, generating
an estimated 551,000 new cases per year, a number that
continues to grow and has yet to be optimally addressed.
Despite this significant disease burden, Indonesia's Cataract
Source: IAPB, BPJS, Ministry of Health, Company’s Research Surgical Rate stands at approximately 2,300 procedures per
million population, roughly 2-3x below regional peers such as
Figure 3: Cataract Surgical Rate India (~6,000) and Thailand (~7,000), reflecting both limited
surgical capacity and substantial unmet demand.
Indonesia ~ 2,300
As the only definitive treatment for cataracts, IOL presents a
India ~ 6,000 + structurally compelling growth opportunity. OMED's entry into
domestic IOL manufacturing positions the company to
Thailand ~ 7,000 + capture this demand while reducing Indonesia's reliance on
imported devices, aligned with the government's broader
Developed Countries ~ 8,000 +
push for domestic healthcare self-sufficiency.
Source: IAPB, BPJS, Ministry of Health, Company’s Research
Page 4
Operational Highlights Unaudited
Production Price
(in thousand units) 3M25 3M26 YoY (in IDR) 3M25 3M26 YoY
Sales Volume Average Selling Price
Disposable & Consumables 370,758 679,253 83.2% Disposable & Consumables 602 403 (33.1%)
Wound Care 91,032 101,285 11.3% Wound Care 790 851 7.7%
Antiseptic & Dialysis Fluid 108,029 120,506 11.5% Antiseptic & Dialysis Fluid 462 467 0.9%
Diagnostic & Equipment 696 4,711 577.2% Diagnostic & Equipment 60,492 15,066 (75.1%)
Walking Aids & Rehab 468 514 9.8% Walking Aids & Rehab 43,739 47,150 7.8%
Biotech & Lab 40,302 35,617 (11.6%) Biotech & Lab 467 1,584 239.2%
Hospital Furniture 13 11 (12.9%) Hospital Furniture 774,997 406,228 (47.6%)
Total 611,298 941,897 54.1%
Source: Company
Financial Highlights (IDR Bn)
Revenue EBITDA Net Profit
2,064
1,886
1,737
31.4% 22.4% 22.6% 23.0% 17.2% 17.9% 16.8% 17.3%
20.7% 21.6% 14.9%
461.9 324.0 368.9
572.2 359.5 407.3 259.4
436.3
98.4 131.4 73.1 99.0
2023 2024 2025 1Q25 1Q26 2023 2024 2025 1Q25 1Q26 2023 2024 2025 1Q25 1Q26
Revenue Growth EBITDA EBITDA Margin Net Profit Net Profit Margin
Assets Liabilities Equity
2,937 2,496 2,569
2,826
2,507 2,581 2,245
2,069
1,726 466 437 1,245
368
438 330
2021 2022 2023 2024 1Q25 2021 2022 2023 2024 1Q25 2021 2022 2023 2024 1Q25
Source: Company
Page 5
DISCLAIMER This document is prepared by PT Jayamas Medica Industri Tbk (“the Company”) for informational purposes only and does not constitute an offer, solicitation, or recommendation to buy or sell any securities of the Company. The information contained herein may include forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update or revise any forward-looking statements as a result of new information, future developments, or otherwise. Investors are advised to exercise their own judgment and consult with appropriate professional advisors before making any investment decisions.
Names mentioned 5 people and organisations named in the text · linked when the evidence is strong
unresolved
org
PT Intisumber Hasilsempurna
p.1
unresolved
org
Ministry of Health
p.3 ×2
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.